40:
153:
Sunovion was founded as
Sepracor, Inc. in 1984 by Timothy J. Barberich, Steve Matson, and Bob Bratzler. Sepracor completed its initial public offering in 1991, trading on NASDAQ under the ticker SEPR. On October 12, 2010, Sepracor, Inc. was acquired by and became a standalone subsidiary of Sumitomo
271:
On April 3, 2023, Sunovion
Pharmaceuticals, an indirect, wholly owned subsidiary of Sumitomo Pharma Co. Ltd, announced that it will combine with Sumitomo Pharma’s other affiliate companies Sumitomo Pharma America Holdings, Inc., Sumitovant Biopharma Ltd., Myovant Sciences, Inc., Urovant Sciences,
149:
became part of
Sumitomo Pharma America, Inc., a biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need spanning psychiatry and neurology, oncology, urology, women's health, rare disease, and cell and gene therapies.
518:
438:
510:
154:
Pharma of Japan (then known as
Sumitomo Dainippon Pharma). In April 2023, Sumitomo Pharma announced the combination of its U.S. subsidiaries, including Sunovion, to form Sumitomo Pharma America (SMPA).
583:
430:
578:
197:, under the direction of Gunnar Aberg and John McCullough. The primary source of its revenue in the late 1990s - early 2000s was the approximately $ 600 million annually from its
593:
563:
568:
603:
558:
382:
206:
162:
Sepracor completed its initial public offering in 1991 at a market cap of $ 160M. The company's initial focus was on the separation and purification of
182:, after the latter was required to carry a warning about potentially fatal cardiac arrhythmia. This purified compound would later be marketed as
598:
405:
214:
272:
Inc., Enzyvant
Therapeutics, Inc., and Sumitomo Pharma Oncology, Inc. to form Sumitomo Pharma America, Inc. (SMPA), effective July 1, 2023.
573:
259:
Sepracor was acquired by then-Sumitomo
Dainippon Pharma in 2010 for $ 2.6B. Sepracor would become an indirect, wholly owned subsidiary of
588:
474:
431:"FDA Approves Sepracor, Inc.'s BROVANA(TM) (Arformoterol Tartrate) Inhalation Solution For Chronic Obstructive Pulmonary Disease"
170:. The strategy was to present larger pharmaceuticals with patented, purified active ingredients for expiring products. In 1993,
190:
374:
511:"Sumitomo Pharma Subsidiary Companies in the U.S., Including Sunovion, to Combine and Form Sumitomo Pharma America"
78:
186:, but Sepracor would not profit significantly from its launch, a result of less-than favorable partnership terms.
375:"Sumitomo Pharma America Launches as New Combined Organization with Expanded Scale, Resources & Capabilities"
324:
260:
340:
299:
The following is an illustration of the company's major mergers and acquisitions and historical predecessors:
228:
at
Sepracor's facilities and supervised by Bial. Aptiom subsequently received FDA approval in 2013 to treat
225:
332:
348:
316:
194:
248:
244:
171:
209:(FDA) in December 2004 and launched in April 2005. In 2006, the FDA approved Sepracor's drug
485:
127:
111:
122:
552:
240:
229:
460:
183:
60:
406:"Sumitomo Pharma tidies up 7 units into one combined US entity in spring cleaning"
287:
178:, partnered with Sepracor to develop a purified version of its antihistamine,
167:
50:
239:, an atypical antipsychotic drug, received FDA approval for the treatment of
281:
39:
17:
210:
202:
198:
179:
115:
107:
236:
224:
agreed with the company to produce and market its antiepileptic drug
175:
163:
103:
99:
243:
and in 2013, received a secondary approval for the treatment of
221:
189:
Sepracor's subsequent products were focused on the treatment of
475:"Sunovion Pharmaceuticals Inc. announces company name change"
543:
137:
133:
121:
95:
85:
74:
66:
56:
46:
584:Companies based in Middlesex County, Massachusetts
579:Pharmaceutical companies of the United States
8:
594:Pharmaceutical companies established in 1984
564:Biotechnology companies of the United States
215:chronic obstructive pulmonary disease (COPD)
32:
569:Biotechnology companies established in 1984
267:Combination to form Sumitomo Pharma America
604:American subsidiaries of foreign companies
38:
31:
255:Acquisition by Sumitomo Dainippon Pharma
559:Companies formerly listed on the Nasdaq
366:
441:from the original on February 19, 2023
201:franchise of drugs. The insomnia drug
7:
404:Armstrong, Annalee (April 3, 2023).
290:(85:15 ratio) (SEP-4199) – phase III
521:from the original on July 13, 2023
484:. October 12, 2010. Archived from
385:from the original on July 13, 2023
205:(eszopiclone) was approved by the
25:
91:Antony Loebel (President and CEO)
517:(Press release). April 3, 2023.
295:List of mergers and acquisitions
461:"Bial - caring for your health"
207:US Food and Drug Administration
544:Sunovion Pharmaceuticals, Inc.
1:
599:2010 mergers and acquisitions
147:Sunovion Pharmaceuticals Inc.
33:Sunovion Pharmaceuticals Inc.
574:Biopharmaceutical companies
325:New England Pharmaceuticals
288:Aramisulpride:esamisulpride
620:
589:Marlborough, Massachusetts
276:Products Under Development
79:Marlborough, Massachusetts
341:Elevation Pharmaceuticals
263:and renamed to Sunovion.
261:Dainippon Sumitomo Pharma
37:
138:http://www.sunovion.com
230:partial onset seizures
191:central nervous system
27:Pharmaceutical company
349:Cynapsus Therapeutics
308:(Previously-known as
284:(SEP-856) – phase III
195:respiratory disorders
333:Oryx Pharmaceuticals
437:. October 9, 2006.
245:depressive episodes
34:
249:Bipolar I Disorder
172:Marion Merrell Dow
381:. July 10, 2023.
353:
345:
337:
329:
321:
313:
145:On July 1, 2023,
143:
142:
16:(Redirected from
611:
531:
530:
528:
526:
507:
501:
500:
498:
496:
491:on March 4, 2016
490:
479:
471:
465:
464:
457:
451:
450:
448:
446:
427:
421:
420:
418:
416:
401:
395:
394:
392:
390:
371:
351:
343:
335:
327:
319:
307:
247:associated with
174:, now a part of
42:
35:
21:
619:
618:
614:
613:
612:
610:
609:
608:
549:
548:
540:
535:
534:
524:
522:
509:
508:
504:
494:
492:
488:
477:
473:
472:
468:
459:
458:
454:
444:
442:
429:
428:
424:
414:
412:
403:
402:
398:
388:
386:
373:
372:
368:
363:
358:
317:IBF Biotechnics
297:
278:
269:
257:
160:
158:Company history
128:Sumitomo Pharma
114:
112:Lonhala Magnair
110:
106:
102:
88:
81:, United States
61:Pharmaceuticals
28:
23:
22:
15:
12:
11:
5:
617:
615:
607:
606:
601:
596:
591:
586:
581:
576:
571:
566:
561:
551:
550:
547:
546:
539:
538:External links
536:
533:
532:
502:
466:
452:
422:
410:Fierce Biotech
396:
365:
364:
362:
359:
357:
356:
355:
354:
346:
338:
330:
322:
301:
296:
293:
292:
291:
285:
277:
274:
268:
265:
256:
253:
159:
156:
141:
140:
135:
131:
130:
125:
119:
118:
97:
93:
92:
89:
86:
83:
82:
76:
72:
71:
68:
64:
63:
58:
54:
53:
48:
44:
43:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
616:
605:
602:
600:
597:
595:
592:
590:
587:
585:
582:
580:
577:
575:
572:
570:
567:
565:
562:
560:
557:
556:
554:
545:
542:
541:
537:
520:
516:
515:BUSINESS WIRE
512:
506:
503:
487:
483:
476:
470:
467:
462:
456:
453:
440:
436:
432:
426:
423:
411:
407:
400:
397:
384:
380:
379:Yahoo Finance
376:
370:
367:
360:
350:
347:
342:
339:
334:
331:
326:
323:
318:
315:
314:
311:
306:
303:
302:
300:
294:
289:
286:
283:
280:
279:
275:
273:
266:
264:
262:
254:
252:
250:
246:
242:
241:schizophrenia
238:
233:
231:
227:
223:
218:
216:
212:
208:
204:
200:
196:
192:
187:
185:
181:
177:
173:
169:
165:
157:
155:
151:
148:
139:
136:
132:
129:
126:
124:
120:
117:
113:
109:
105:
101:
98:
94:
90:
84:
80:
77:
73:
69:
65:
62:
59:
55:
52:
49:
45:
41:
36:
30:
19:
523:. Retrieved
514:
505:
493:. Retrieved
486:the original
481:
469:
455:
445:February 10,
443:. Retrieved
434:
425:
413:. Retrieved
409:
399:
387:. Retrieved
378:
369:
309:
304:
298:
270:
258:
234:
219:
188:
161:
152:
146:
144:
75:Headquarters
47:Company type
29:
495:October 27,
168:metabolites
166:and active
553:Categories
361:References
352:(Acq 2016)
344:(Acq 2012)
336:(Acq 2008)
328:(Acq 1995)
320:(Acq 1991)
87:Key people
51:Subsidiary
282:Ulotaront
235:In 2010,
220:In 2008,
213:to treat
525:July 13,
519:Archived
482:Sunovion
439:Archived
435:BioSpace
415:July 13,
389:July 13,
383:Archived
310:Sepracor
305:Sunovion
96:Products
57:Industry
18:Sepracor
211:Brovana
203:Lunesta
199:Xopenex
184:Allegra
180:Seldane
164:isomers
134:Website
116:Lunesta
108:Kynmobi
67:Founded
237:Latuda
226:Aptiom
176:Sanofi
123:Parent
104:Aptiom
100:Latuda
489:(PDF)
478:(PDF)
527:2023
497:2010
447:2020
417:2023
391:2023
222:Bial
193:and
70:1984
555::
513:.
480:.
433:.
408:.
377:.
251:.
232:.
217:.
529:.
499:.
463:.
449:.
419:.
393:.
312:)
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
